Lucanix (belagenpumatucel-L) is a TGF-β2 antisense gene-modified allogeneic tumour cell vaccine that has completed phase II evaluation and is currently in a phase III study against placebo in non-small cell lung cancer (NSCLC) patients as maintenance therapy after front-line treatment[117]. The gene discussed is TGFB2; the disease is neoplasm.